Why the study?
The study was designed to evaluate P-wave dispersion as a predictor of atrial fibrillation and investigate its relationship with inflammation parameters in patients with newly diagnosed COVID-19.
Is P-wave dispersion prolonged in newly diagnosed COVID-19 patients and does it correlate with inflammation and incident atrial fibrillation?
Is P-wave dispersion prolonged in newly diagnosed COVID-19 patients and does it correlate with inflammation and incident atrial fibrillation?
Answers are grounded in this paper and cite their sources.
P-wave dispersion is prolonged in newly diagnosed COVID-19 patients, correlates with inflammatory markers, and may help predict the risk of incident atrial fibrillation.
AIM: The aim of the current study was to evaluate P-wave dispersion (PWD) as a predictor of atrial fibrillation in patients with newly diagnosed COVID-19. In addition, the relationship between the PWD and inflammation parameters was investigated. METHODS: A total of 140 newly diagnosed COVID-19 patients and 140 age- and sex-matched healthy individuals were included in the study. The risk of atrial fibrillation was evaluated by calculating the electrocardiographic PWD. C-reactive protein (CRP), white blood cell, neutrophil and neutrophil-to-lymphocyte ratio (NLR) were measured in patients with newly diagnosed COVID-19. RESULTS: PWD, white blood cell, NLR and CRP levels were significantly higher in the COVID-19 group than the control group. There was a significant positive correlation between PWD and CRP level (rs = 0.510, P < 0.001) and NLR in COVID-19 group (rs = 0.302, P = 0.001). In their follow-up, 13 (9.3%) patients, 11 of whom were in the ICU, developed new atrial fibrillation. CONCLUSION: Our study showed for the first time in literature that the PWD, evaluated electrocardiographically in patients with newly diagnosed COVID-19, was prolonged compared with normal healthy individuals. A positive correlation was found between PWD, CRP level and NLR. We believe that pretreatment evaluation of PWD in patients with newly diagnosed COVID-19 would be beneficial for predicting atrial fibrillation risk.
No takes yet. Share an insight, caveat, or question.
Yenerçağ et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: